Major depression, a common mental illness affecting millions of people worldwide, is one of the leading causes of morbidity and has a significant economic cost. Although the mechanisms of action are not well understood, antidepressants, including serotonin-selective reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), have been used for the treatment of depression, anxiety and other psychiatric disorders.1 Here we identified a Wnt signaling inhibitor, secreted frizzled-related protein (sFRP3), as a molecular target of antidepressant treatments in rodent models, and revealed the significant association of three single-nucleotide polymorphisms (SNPs) in FRZB (the sFRP3 human ortholog) with early antidepressant responses in a clinical cohort.
|Number of pages||2|
|Early online date||4 Dec 2012|
|Publication status||Published - 1 Sep 2013|